News
MedPage Today on MSN15h
First-Line Immunotherapy Combo Boosts Survival in Unresectable Liver CancerFirst-line treatment with nivolumab (Opdivo) and ipilimumab (Yervoy) significantly improved survival compared with lenvatinib ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback